Limitations of the α-Synuclein Seed Amplification Assay in Clinical Practice-Reference-Cited by-同舟云学术

Limitations of the α-Synuclein Seed Amplification Assay in Clinical Practice

Published:2024-09-01 Issue:9 Volume:81 Page:905
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Morris Huw R.¹²,Lees Andrew J.³⁴

Affiliation:

1. Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, University College London, London, United Kingdom

2. The Aligning Science Across Parkinson’s Collaborative Research Network, Chevy Chase, Maryland

3. Reta Lila Weston Institute of Neurological Studies, University College London Queen Square Institute of Neurology, London, United Kingdom

4. The National Hospital for Neurology and Neurosurgery, London, United Kingdom

Abstract

This Viewpoint cautions against premature adoption of the α-synuclein seed amplification assay as a biomarker test for Parkinson disease in general neurology practice.

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2822066/jamaneurology_morris_2024_vp_240008_1725483540.0611.pdf

Reference10 articles.

1. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using a-synuclein seed amplification: a cross-sectional study.;Siderowf;Lancet Neurol,2023

2. A biological definition of neuronal a-synuclein disease: towards an integrated staging system for research.;Simuni;Lancet Neurol,2024

3. A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria.;Höglinger;Lancet Neurol,2024

4. a-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid-a systematic review and meta-analysis.;Grossauer;Movement Disord Clin Pract,2023

5. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease.;Gibb;J Neurol Neurosurg Psychiatry,1988